- Home
- TCPC vs RLAY Comparison
TCPC vs RLAY Comparison
Compare TCPC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- RLAY
- Stock Information
- Founded
- TCPC 2006
- RLAY 2015
- Country
- TCPC United States
- RLAY United States
- Employees
- TCPC N/A
- RLAY N/A
- Industry
- TCPC Finance/Investors Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCPC Finance
- RLAY Health Care
- Exchange
- TCPC Nasdaq
- RLAY Nasdaq
- Market Cap
- TCPC 767.3M
- RLAY 620.4M
- IPO Year
- TCPC 2012
- RLAY 2020
- Fundamental
- Price
- TCPC $7.99
- RLAY $2.72
- Analyst Decision
- TCPC Hold
- RLAY Strong Buy
- Analyst Count
- TCPC 5
- RLAY 10
- Target Price
- TCPC $8.63
- RLAY $19.33
- AVG Volume (30 Days)
- TCPC 744.3K
- RLAY 2.6M
- Earning Date
- TCPC 04-30-2025
- RLAY 05-01-2025
- Dividend Yield
- TCPC 17.65%
- RLAY N/A
- EPS Growth
- TCPC N/A
- RLAY N/A
- EPS
- TCPC N/A
- RLAY N/A
- Revenue
- TCPC $259,437,390.00
- RLAY $10,007,000.00
- Revenue This Year
- TCPC N/A
- RLAY N/A
- Revenue Next Year
- TCPC N/A
- RLAY $544.28
- P/E Ratio
- TCPC N/A
- RLAY N/A
- Revenue Growth
- TCPC 23.94
- RLAY N/A
- 52 Week Low
- TCPC $7.67
- RLAY $2.69
- 52 Week High
- TCPC $11.52
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- TCPC 41.05
- RLAY 33.65
- Support Level
- TCPC $7.67
- RLAY $3.05
- Resistance Level
- TCPC $7.85
- RLAY $3.08
- Average True Range (ATR)
- TCPC 0.14
- RLAY 0.26
- MACD
- TCPC 0.04
- RLAY -0.03
- Stochastic Oscillator
- TCPC 53.33
- RLAY 2.46
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).